• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Bluebird Bio Looks Set to Soar Upward

Meal worms not needed to give it strength.
By BRUCE KAMICH
Jan 31, 2017 | 09:03 AM EST
Stocks quotes in this article: BLUE

While Silicon Valley CEOs were up in arms against President Donald Trump's travel ban for citizens of seven countries, the silence was deafening in the corner of the big biotech companies, our political correspondent Adam Feuerstein wrote in a recent article. Still, some of the the smaller firms in the sector came out against the ban. 

Nick Leschly, President & CEO of bluebird bio (BLUE) said, according to the article: "Disease knows no boundaries. We as a country and the U.S. life sciences sector specifically need more good scientists to continue to advance medical innovation and new discoveries for patients around the globe. We at Bluebird Bio emphatically support and celebrate a diverse population. We oppose any policies that inhibit our ability to attract and retain the best and brightest scientific and business minds from all over the world."

The company has been doing well, and the charts show its stock is about to fly, s our favorite technical indicators are getting set for an upside breakout.

In this one-year daily bar chart of BLUE, above, we can see two different price patterns. On the left side of the chart, BLUE is trading sideways in a relatively narrow range between $35 and $55. In August, the pattern changes. Prices are still in a mostly sideways pattern from August, but the up and down range spans $45 dollars. Volume is heavier. Prices are now above the rising 50-day moving average line and the rising 200-day moving average line.

There is more "action" in the On-Balance-Volume (OBV) line, indicating more aggressive buying. Last, the Moving Average Convergence Divergence (MACD) oscillator is above the zero line most of the time since August.

In this three-year weekly chart of BLUE, above, try not to focus on the big rally and decline. Pay more attention to the past year. Prices are now above the rising 40-week moving average line. The weekly OBV line has been stable and the weekly MACD oscillator is above the zero line (bullish).

This Point and Figure chart presents the price action in a different way. Here you can see that a trade at $72 will be a breakout for BLUE and yield us a potential initial price target of $85.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Markets | How-to | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login